- Home
- NFJ vs COLL Comparison
NFJ vs COLL Comparison
Compare NFJ & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NFJ | COLL |
|---|---|---|
| Founded | 2005 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NFJ | COLL |
|---|---|---|
| Price | $12.85 | $33.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $51.17 |
| AVG Volume (30 Days) | 216.3K | ★ 520.9K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 9.01% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | N/A | $5.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $19.22 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $10.02 | $23.23 |
| 52 Week High | $13.92 | $50.79 |
Technical Indicators
Market Signals| Indicator | NFJ | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 46.46 | 31.05 |
| Support Level | $12.42 | $31.01 |
| Resistance Level | $13.14 | $32.92 |
| Average True Range (ATR) | 0.20 | 1.18 |
| MACD | 0.05 | 0.17 |
| Stochastic Oscillator | 64.06 | 19.90 |
Price Performance
Historical ComparisonAbout NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.